Wesley was four, mostly nonverbal, and just learning to walk. Two summers of LSVT BIG® and LSVT LOUD® later, his family can’t get him off the stairs or get him to stop talking.
Continue Reading →
Although LSVT LOUD was initially developed for the treatment of hypokinetic dysarthria in Parkinson’s disease, numerous compelling single-subject and small-group studies by researchers from around the world, including the United States, Italy, and Japan, have shown that LSVT LOUD is highly effective for individuals with dysarthria of spastic, mixed, and other types in the atypical parkinsonism disorders PSP and MSA. For this reason, intervention with LSVT LOUD was considered in this case of CBS, which was confirmed as CBD. This is the first report of LSVT LOUD for the atypical parkinsonism disorder CBD.
Continue Reading →
Parkinson’s disease is now the fastest-growing neurological condition in the world, with global cases projected to more than double, from roughly 11.9 million in 2021 to 25.2 million by 2050, and Asia is set to carry the heaviest share of that burden, with the highest prevalence rates of any region. As diagnoses climb across the region, the need for accessible, evidence-based rehabilitation care has never been more urgent.
Because of this growing need, on July 17-18, 2026, for the first time ever, LSVT BIG® Training and Certification was offered in-person in Southeast Asia, and the response exceeded every expectation.
Continue Reading →